RMD open

Starting tirzepatide and biologic treatments together improves patient-reported outcomes in obese psoriatic arthritis

Updated

Abstract

Clinical outcomes were evaluated in obese patients with psoriatic arthritis (PsA) over 6 months.

  • Patients who started tirzepatide alongside biologic therapy may experience different clinical outcomes compared to those who began biologic therapy alone.
  • The evaluation focuses specifically on patients with obesity and PsA, highlighting a specific subgroup.
  • Outcomes assessed include various clinical parameters relevant to the management of PsA.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Competing interests: None declared.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free